For Immediate Release

Chicago, IL – March 22, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Walt Disney Co. DIS, Morgan Stanley MS, Stryker Corp. SYK, Shopify Inc. SHOP and Delta Air Lines, Inc. DAL.

Here are highlights from Thursday’s Analyst Blog:

Top Stock Reports for Disney, Morgan Stanley and Stryker

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Co., Morgan Stanley and Stryker Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Disney's shares have outperformed the Zacks Media Conglomerates industry over the past year (+22.7% vs. +6.8%). The Zacks analyst believes that recent attractions in places like Hong Kong and Paris should boost the company’s theme park business.

However, declining ad revenues, increasing programming and production costs at Media and Entertainment Distribution segments and stiff competition in the streaming market remain major tailwinds.

(You can read the full research report on Disney here >>>)

Morgan Stanley’s shares have underperformed the Zacks Financial – Investment Bank industry over the last six months (+9.7% vs. +20.0%). The Zacks analyst believes that volatility in the capital markets has continued to hurt the company’s Institutional Securities segment. Also, elevated costs are likely to impact profitability.

Yet, Morgan Stanley’s trading and investment banking segments turned around slightly in the fourth quarter of 2023. The company's brand-new strategic alliance with Mitsubishi UFJ will bolster its presence in Japan. Also, inorganic expansion efforts will aid.

(You can read the full research report on Morgan Stanley here >>>)

Shares of Stryker have outperformed the Zacks Medical - Products industry over the past year (+29.7% vs. +6.6%). Per the Zacks analyst, strong business in the United States as well as globally have created optimism about the company’s prospects. Heavy demand for the company’s existing product line as well as new launches have also aided.

However, inflationary pressure and supply-chain challenges continue to plague Stryker. Stiff competition in the MedTech space also remains a headwind.